Herbalife
HLF
12.65
+0.07
+0.56%
Herbalife
US · HLF
#3080 by market cap
Listed 2004
12.65
+0.07
+0.56%
Live - 5344 symbols - heartbeat 238s ago
· 2026-10-08 04:01
Pre-market
12.65
0.00%
After-hours
12.65
0.00%
- Market cap
- 1.33B
- P/E (TTM)i
- 8.11
- P/Bi
- -2.79
- EPSi
- 2.20
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on HLF?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.38, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.89% YoY
Margins
- Gross margin
- 77.87%
- Operating margin
- 9.55%
- Net margin
- 4.53%
Key ratios & quality
- Enterprise valuei
- 3.00B
- Altman Z-Scorei
- 2.38
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.89B | 4.88B | 5.54B | 5.80B | 5.20B | 5.06B | 4.99B | 5.04B |
| Gross profit | 3.97B | 3.92B | 4.39B | 4.56B | 4.03B | 3.87B | 3.89B | 3.92B |
| Selling & admin expenses | 1.96B | 1.94B | 2.08B | 2.01B | 1.81B | 3.53B | 3.51B | 3.45B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 683.10M | 568.10M | 640.60M | 734.10M | 545.20M | 356.40M | 385.90M | 481.00M |
| Pretax profit | 464.20M | 451.40M | 516.40M | 560.80M | 424.80M | 203.00M | 169.40M | 275.10M |
| Tax | 167.60M | 140.40M | 143.80M | 113.60M | 103.50M | 60.80M | -84.90M | 47.30M |
| Net profit | 296.60M | 311.00M | 372.60M | 447.20M | 321.30M | 142.20M | 254.30M | 227.80M |
| Basic EPS | 2 | 2 | 3 | 4 | 3 | 1 | 3 | 2 |
| Diluted EPS | 1.98 | 2.20 | 2.77 | 4.13 | 3.23 | 1.42 | 2.50 | 2.20 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.26B | 1.27B | 1.28B | 1.32B | 1.33B |
| Gross profit | 956.50M | 982.20M | 989.50M | 994.70M | 1.03B | 1.03B |
| Selling & admin expenses | 833.70M | 854.40M | 447.60M | 2.12B | 893.20M | 902.20M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 122.80M | 132.60M | 125.80M | 99.80M | 138.40M | 128.30M |
| Pretax profit | 70.80M | 79.00M | 74.80M | 50.50M | 91.60M | -3.70M |
| Tax | 20.40M | 29.80M | 31.70M | -34.60M | 30.40M | 22.80M |
| Net profit | 50.40M | 49.20M | 43.10M | 85.10M | 61.20M | -26.50M |
| Basic EPS | 1 | 0 | 0 | 1 | 1 | 0 |
| Diluted EPS | 0.49 | 0.48 | 0.42 | 0.81 | 0.57 | -0.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.81B | 1.49B | 1.78B | 1.43B | 1.36B | 1.40B | 1.14B | 1.14B |
| Cash & ST investments | 1.20B | 839.40M | 1.05B | 601.50M | 508.00M | 575.20M | 415.30M | 353.10M |
| Inventory | 381.80M | 436.20M | 501.40M | 575.70M | 580.70M | 505.20M | 475.40M | 511.70M |
| Total assets | 2.79B | 2.68B | 3.08B | 2.82B | 2.73B | 2.81B | 2.73B | 2.79B |
| Total current liabilities | 1.59B | 964.40M | 1.13B | 1.08B | 976.60M | 1.28B | 1.23B | 1.01B |
| Short-term debt | 678.90M | 61.50M | 58.40M | 72.20M | 66.90M | 349.00M | 323.20M | 56.40M |
| Long-term debt | 1.77B | 1.78B | 2.41B | 2.73B | 2.66B | 2.25B | 1.98B | 1.97B |
| Total liabilities | 3,513,200,000.00 | 3,068,600,000.00 | 3,932,200,000.00 | 4,211,300,000.00 | 3,997,900,000.00 | 3,869,700,000.00 | 3,529,200,000.00 | 3,295,300,000.00 |
| Total equity | -723.40M | -390.00M | -856.10M | -1.39B | -1.27B | -1.06B | -801.10M | -509.40M |
| Retained earnings | -526.30M | -215.30M | -687.40M | -1.17B | -1.20B | -1.06B | -808.00M | -579.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.09B | 1.10B | 1.11B | 1.14B | 1.25B | 1.17B |
| Cash & ST investments | 329.40M | 320.90M | 305.50M | 353.10M | 451.20M | 370.50M |
| Inventory | 488.00M | 513.10M | 512.50M | 511.70M | 494.60M | 507.70M |
| Total assets | 2.68B | 2.74B | 2.70B | 2.79B | 2.88B | 2.86B |
| Total current liabilities | 1.13B | 1.09B | 999.90M | 1.01B | 1.02B | 973.50M |
| Short-term debt | 258.20M | 206.90M | 58.30M | 56.40M | 45.10M | 48.00M |
| Long-term debt | 1.98B | 1.97B | 2.00B | 1.97B | 1.98B | 2.00B |
| Total liabilities | 3,420,300,000.00 | 3,390,500,000.00 | 3,303,200,000.00 | 3,295,300,000.00 | 3,309,400,000.00 | 3,324,600,000.00 |
| Total equity | -736.00M | -654.40M | -606.00M | -509.40M | -434.20M | -466.90M |
| Retained earnings | -757.60M | -708.30M | -665.10M | -579.70M | -517.80M | -544.10M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 648.40M | 457.50M | 628.60M | 460.30M | 352.50M | 357.50M | 285.40M | 333.30M |
| Depreciation & amortization | 100.40M | 97.70M | 100.30M | 107.60M | 115.40M | 113.30M | 121.40M | 121.20M |
| Free cash flow | 564.40M | 351.40M | 516.60M | 308.90M | 196.10M | 222.50M | 163.40M | 252.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -750.30M | -16.70M | -923.50M | -1.01B | -146.70M | -11.00M | -8.30M | -8.20M |
| Ending cash balance | 1.22B | 847.50M | 1.05B | 610.40M | 516.30M | 595.50M | 438.10M | 375.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 200.00K | 96.00M | 138.80M | 98.30M | 113.80M | 32.90M |
| Depreciation & amortization | 30.70M | 30.50M | 30.70M | 29.30M | 29.40M | 31.40M |
| Free cash flow | -18.10M | 73.20M | 118.00M | 79.80M | 102.90M | 21.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -2.20M | -4.60M | -1.30M | -100.00K | -700.00K | -9.30M |
| Ending cash balance | 351.00M | 343.60M | 328.00M | 375.30M | 473.00M | 393.40M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| ROA %i | 10.43 | 11.37 | 12.95 | 15.17 | 11.57 | 5.13 | 9.18 | 8.28 |
| ROIC %i | -- | -- | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13.19 | 12.39 | 11.72 | 12.30 | 10.84 | 7.29 | 7.76 | 9.72 |
| FCF / sales %i | 11.54 | 7.21 | 9.32 | 5.32 | 3.77 | 4.40 | 3.27 | 5.02 |
| Current ratioi | 1.14 | 1.54 | 1.58 | 1.33 | 1.39 | 1.10 | 0.93 | 1.13 |
| Quick ratioi | 0.80 | 0.95 | 1.00 | 0.62 | 0.59 | 0.51 | 0.39 | 0.44 |
| Debt / assetsi | 87.96 | 75.05 | 86.82 | 106.62 | 106.95 | 98.58 | 90.51 | 78.39 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 3.56 | 3.95 | 4.88 | 4.66 | 4.05 | 2.22 | 1.78 | 2.28 |
| Revenue CAGR (3Y) %i | 3.06 | 2.81 | 7.77 | 5.86 | 2.19 | -2.97 | -4.89 | -1.08 |
| Net income CAGR (3Y) %i | -4.37 | 6.15 | 20.32 | 14.67 | 1.09 | -27.46 | -17.15 | -10.77 |
| FCF CAGR (3Y) %i | 0.88 | 16.21 | 1.41 | -18.20 | -17.67 | -24.48 | -19.13 | 8.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 10.52 | 12.18 | 11.98 | 8.28 | 8.60 | 5.87 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.84 | 10.13 | 10.02 | 9.72 | 9.84 | 7.83 |
| FCF / sales %i | 3.32 | 3.48 | 4.37 | 5.02 | 7.28 | 6.20 |
| Current ratioi | 0.97 | 1.01 | 1.11 | 1.13 | 1.23 | 1.20 |
| Quick ratioi | 0.37 | 0.38 | 0.40 | 0.44 | 0.55 | 0.50 |
| Debt / assetsi | 89.43 | 85.74 | 82.03 | 78.39 | 75.90 | 77.12 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 1.89 | 2.21 | 2.26 | 2.28 | 2.41 | 2.10 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Weight management is the largest reported line at 53.72% of revenue, across 5 reported segments.
- Targeted Nutrition follows at 30.22%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Weight management53.72%
Targeted Nutrition30.22%
Energy, Sports, and Fitness13.02%
Outer Nutrition1.60%
Literature, Promotional, and Other1.43%
Quote time 2026-10-08 04:01:04 · For reference only, not investment advice and not tailored to your situation.